“New” Ocaliva (obeticholic acid) is a prescription medicine used for the treatment of primary biliary cholangitis (PBC) in adult patients. OCALIVA is taken in combination with another medicine called ursodeoxycholic acid (UDCA), or, for people who cannot tolerate UDCA, OCALIVA can be taken by itself.
The effectiveness of OCALIVA in these patients is based on a study that showed a reduction in the liver enzyme alkaline phosphatase (ALP). There is no clinical information currently available to show if patients treated with OCALIVA live longer or if their symptoms improve. There are ongoing studies to find out how OCALIVA works over a longer period of time.
Ocaliva is the first treatment approved for PBC in over 20 years.
Interconnect Ocaliva’s Patient Financial Assistance can usually help patients without insurance, low income and even some who have insurance with deductibles (U.S. only). Visit their site or call (844) 622-4278
Learn more about PBC at Ocaliva’s Patient’s PBC Site.